Table 3 Comparison of patient characteristics between TCGA training and testing cohorts

		Training (133)	Testing (29)	p-value
Recurrence outcome [n]	Late	75	17	1.0
Recurrence outcome [n]	Early	58	12	1.0
Tumor grade [n]	Grade 2	51	11	0.955
	Grade 3	62	13
	Grade 4	20	5
Race [n]^a	White	121	28	0.872
	African American or Black	8	1
	American Indian or Alaska Native	2	0
	Asian	1	0
Hispanic or Latino [n]^a	No	119	27	0.73
Hispanic or Latino [n]^a	Yes	4	1	0.73
Histology [n]^b	Astrocytoma	59	14	0.903
	Glioblastoma	46	8
	Oligodendroglioma	19	5
	Astrocytoma wildtype	9	2
IDH & 1p19q codeletion status [n]	IDH-mutant, non-codeleted	59	14	0.778
	IDH-wildtype	55	10
	IDH-mutant, codeleted	19	5
Vital status [n]	Deceased	80	17	1.0
Vital status [n]	Alive	53	12	1.0
Days to recurrence	Median	427.0	468.0	0.585
Days to recurrence	IQR	622.0	545.0	0.585
Age [yr]	Median	47	39	0.191
Age [yr]	IQR	22.0	28.0	0.191

Chi-square tests of independence were used for all categorical variables, unless expected cell counts were <5 in a 2 × 2 contingency table, in which case we applied Fisher’s exact test. The Mann–Whitney U test was used for age and days to recurrence. All statistical tests were two-sided (significance α = 0.05).
Bracketed numbers next to Training/Testing indicate the number of included patients.
^aRace and ethnicity were unavailable for 1 and 11 patients, respectively.
^bHistology represents the reassigned labels, as described in Methods and Fig. 2.

Quick links

Search